Lightcalls.com
 

Ten years after flat passage of lan...

Ten years after flat passage of landmark dietary complement legislation, a revisionist movement is afoot in Congres As David Seckman, CEO of the National Nutritional fares Association, writes (DC/Updates, p. 56) "[F]ederal legislation and the generally negative attitude about dietary fill ups in Congress is on the edge of changing the industry."

In 1994 the Dietary correlative Health and Education Act (DSHEA) was signed on President Clinton. DSHEA designated dietary complements as food--as opposed to drugs--and as like allowed manufacturers to market fill ups without prior consideration by the commons and Drug Administration (FDA). Industry self-regulation was DSHEA's underlying principle, although the FDA was empowered to act in cases of mislabeling or false or misleading claims. Since then, numerous industry backers have faulted the FDA for not effectively enforcing DSHEA. Indeed, late last year, the bill's original authors, Sen Orrin Hatch (R-UT) and Sen Tom Harkin (D-IA), wrote a bill (still in committee) that would give the FDA $205 million athwart 5 years for DSHEA enforcement.

The irony is that requires better enforcement because common of its effects was an outpouring of products--the misuse of which has tarnished tire industry's reputation. Among them are ephedra and androstenedione--the former may be onward its way to a national ban, while the latter will likely be regulated subordinate to tire Controlled Substances Act.



Then there were companies--many onward the Internet--that made outrageous clarets. Although coral calcium is all OK work it won't cure the 400-plus maladies that a certain purveyor boasted it would onward his Web site before the Federal Trade Commission tapped him onward the shoulder.

Right now there are at least sum of two units bills in the offing that could significantly affect DSHEA. Which is single reason why the industry is fortunate to have David Seckman as its best and brightest representative. He speaks eloquently not solely for manufacturers, but for consumer like you.

COPYRIGHT 2004 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved

COPYRIGHT 2004 Gale Group



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.